Recently, SMAPs demonstrated efficacy through binding to PP2A in in vivo models of Burkitt’s lymphoma, non-small cell lung cancer, and triple-negative breast cancer—all Myc-driven cancers, representing Myc amplification, post-translational stabilization, and overexpression [161]. The gene discussed is MYC; the disease is Burkitt lymphoma.